Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet

Commentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases

Commentary on Twitter

NEW—Chinese #COVID19 vaccine candidate (CoronaVac) based on inactivated SARS-CoV-2 virus appears safe & induces an immune response in healthy volunteers: finding from a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial @TheLancetInfDis https://t.co/0AC0fP53dI pic.twitter.com/W3gMdqLzTG

— The Lancet (@TheLancet) November 18, 2020